Krystal Biotech buy melinda
Startpreis
21.11.18
/
50%
18,76 €
Kursziel
28.11.18
21,65 €
Rendite (%)
12,69 %
Endpreis
28.11.18
21,14 €
Zusammenfassung
Diese Einschätzung wurde am 28.11.18 mit einem Endkurs von 21,14 € beendet. Mit einer Rendite von 12,69 % entwickelte sich die Einschätzung BUY ganz nach Plan. melinda hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Krystal Biotech | -0,43 % | -0,43 % | 35,18 % | - |
| iShares Core DAX® | -0,21 % | 2,95 % | 17,33 % | 18,20 % |
| iShares Nasdaq 100 | 1,61 % | 5,88 % | 37,45 % | 56,28 % |
| iShares Nikkei 225® | -0,74 % | -1,26 % | 11,85 % | 5,53 % |
| iShares S&P 500 | 0,27 % | 3,24 % | 29,31 % | 46,37 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion Krystal Biotech diskutieren
SecteurRecherche biotechnologique et médicale Agenda 28/11 | 15:30 Présentation
Operates as a biopharmaceutical company which provides therapies for rare and orphan diseases
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases.
It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments.
The company was founded by Suma M. Krishnan in December 2017and is headquartered in Pittsburgh, PA.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases.
It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments.
The company was founded by Suma M. Krishnan in December 2017and is headquartered in Pittsburgh, PA.
Nombre d'employés : 12 personnes.
(Vom Mitglied beendet)